Effects of peptidyl-prolyl isomerase 1 depletion in animal models of prion diseases

References

• Prusiner SB. Molecular structure, biology, and genetics of prions. Adv Virus Res. 1988;35:83–136. doi:10.1016/S0065-3527(08)60709-5
   PubMed Web of Science ®Google Scholar
• Prusiner SB. Molecular biology of prion diseases. Science. 1991;252(5012):1515–22. doi:10.1126/science.1675487
   PubMed Web of Science ®Google Scholar
• Prusiner SB. Molecular biology and genetics of prion diseases. Philos Trans R Soc Lond B Biol Sci. 1994;343(1306):447–63. doi:10.1098/rstb.1994.0043
   PubMed Web of Science ®Google Scholar
• Prusiner SB. Shattuck lecture-neurodegenerative diseases and prions. N Engl J Med. 2001;344(20):1516–26. doi:10.1056/NEJM200105173442006
   PubMed Web of Science ®Google Scholar
• Tanaka M, Chien P, Naber N, et al. Conformational variations in an infectious protein determine prion strain differences. Nature. 2004;428(6980):323–8. doi:10.1038/nature02392
   PubMed Web of Science ®Google Scholar
• Bartz JC. Prion strain diversity. Cold Spring Harb Perspect Med. 2016;6(12):1–14. doi:10.1101/cshperspect.a024349.
   Web of Science ®Google Scholar
• Dickinson AG, Meikle VM. Host-genotype and agent effects in scrapie incubation: change in allelic interaction with different strains of agent. Mol Gen Genet. 1971;112(1):73–9. doi:10.1007/BF00266934
   PubMedGoogle Scholar
• Fraser H. Diversity in the neuropathology of scrapie-like diseases in animals. Br Med Bull. 1993;49(4):792–809. doi:10.1093/oxfordjournals.bmb.a072647
   PubMed Web of Science ®Google Scholar
• Fraser H, Dickinson AG. The sequential development of the brain lesion of scrapie in three strains of mice. J Comp Pathol. 1968;78(3):301–11. doi:10.1016/0021-9975(68)90006-6
   PubMed Web of Science ®Google Scholar
• Khalili-Shirazi A, Summers L, Linehan J, et al. PrP glycoforms are associated in a strain-specific ratio in native PrPSc. J Gen Virol. 2005;86(Pt 9):2635–44. doi:10.1099/vir.0.80375-0
   PubMedGoogle Scholar
• McKinley MP, Bolton DC, Prusiner SB. A protease-resistant protein is a structural component of the scrapie prion. Cell. 1983;35(1):57–62. doi:10.1016/0092-8674(83)90207-6
   PubMed Web of Science ®Google Scholar
• Peretz D, Williamson RA, Legname G, et al. A change in the conformation of prions accompanies the emergence of a new prion strain. Neuron. 2002;34(6):921–32. doi:10.1016/S0896-6273(02)00726-2
   PubMed Web of Science ®Google Scholar
• Wolf H, Grassmann A, Bester R, et al. Modulation of Glycosaminoglycans Affects PrPSc Metabolism but does not block PrPSc Uptake. J Virol. 2015;89(19):9853–64. doi:10.1128/JVI.01276-15
   PubMed Web of Science ®Google Scholar
• Zhou Z, Xiao G. Conformational conversion of prion protein in prion diseases. Acta Biochim Biophys Sin (Shanghai). 2013;45(6):465–76. doi:10.1093/abbs/gmt027
   PubMed Web of Science ®Google Scholar
• Wang F, Yang F, Hu Y, et al. Lipid interaction converts prion protein to a PrPSc-like proteinase K-resistant conformation under physiological conditions. Biochemistry. 2007;46(23):7045–53. doi:10.1021/bi700299h
   PubMed Web of Science ®Google Scholar
• Silva JL, Cordeiro Y. The “Jekyll and Hyde” Actions of Nucleic Acids on the Prion-like Aggregation of Proteins. J Biol Chem. 2016;291(30):15482–90. doi:10.1074/jbc.R116.733428
   PubMed Web of Science ®Google Scholar
• Deleault NR, Harris BT, Rees JR, et al. Formation of native prions from minimal components in vitro. Proc Natl Acad Sci U S A. 2007;104(23):9741–6. doi:10.1073/pnas.0702662104
   PubMed Web of Science ®Google Scholar
• Supattapone S. Synthesis of high titer infectious prions with cofactor molecules. J Biol Chem. 2014;289(29):19850–4. doi:10.1074/jbc.R113.511329
   PubMed Web of Science ®Google Scholar
• Kim NH, Choi JK, Jeong BH, et al. Effect of transition metals (Mn, Cu, Fe) and deoxycholic acid (DA) on the conversion of PrPC to PrPres. FASEB J. 2005;19(7):783–5. doi:10.1096/fj.04-2117fje
   PubMedGoogle Scholar
• Giannopoulos PN, Robertson C, Jodoin J, et al. Phosphorylation of prion protein at serine 43 induces prion protein conformational change. J Neurosci. 2009;29(27):8743–51. doi:10.1523/JNEUROSCI.2294-09.2009
   PubMed Web of Science ®Google Scholar
• Saborio GP, Permanne B, Soto C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature. 2001;411(6839):810–3. doi:10.1038/35081095
   PubMed Web of Science ®Google Scholar
• Soto C, Saborio GP, Anderes L. Cyclic amplification of protein misfolding: application to prion-related disorders and beyond. Trends Neurosci. 2002;25(8):390–4. doi:10.1016/S0166-2236(02)02195-1
   PubMed Web of Science ®Google Scholar
• Deleault NR, Walsh DJ, Piro JR, et al. Cofactor molecules maintain infectious conformation and restrict strain properties in purified prions. Proc Natl Acad Sci U S A. 2012;109(28):E1938–46. doi:10.1073/pnas.1206999109
   PubMed Web of Science ®Google Scholar
• Torrent J, Marchal S, Tortora P, et al. High pressure, an alternative approach to understand protein misfolding diseases. Cell Mol Biol (Noisy-le-grand). 2004;50(4):377–85.
   PubMed Web of Science ®Google Scholar
• Xiong LW, Raymond LD, Hayes SF, et al. Conformational change, aggregation and fibril formation induced by detergent treatments of cellular prion protein. J Neurochem. 2001;79(3):669–78. doi:10.1046/j.1471-4159.2001.00606.x
   PubMed Web of Science ®Google Scholar
• Deleault NR, Lucassen RW, Supattapone S. RNA molecules stimulate prion protein conversion. Nature. 2003;425(6959):717–20. doi:10.1038/nature01979
   PubMed Web of Science ®Google Scholar
• Supattapone S. Prion protein conversion in vitro. J Mol Med (Berl). 2004;82(6):348–56. doi:10.1007/s00109-004-0534-3
   PubMed Web of Science ®Google Scholar
• Deleault NR, Geoghegan JC, Nishina K, et al. Protease-resistant prion protein amplification reconstituted with partially purified substrates and synthetic polyanions. J Biol Chem. 2005;280(29):26873–9. doi:10.1074/jbc.M503973200
   PubMed Web of Science ®Google Scholar
• Geoghegan JC, Valdes PA, Orem NR, et al. Selective incorporation of polyanionic molecules into hamster prions. J Biol Chem. 2007;282(50):36341–53. doi:10.1074/jbc.M704447200
   PubMed Web of Science ®Google Scholar
• Lu KP, Hanes SD, Hunter T. A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature. 1996;380(6574):544–7. doi:10.1038/380544a0
   PubMed Web of Science ®Google Scholar
• Lu KP, Zhou XZ. The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nat Rev Mol Cell Biol. 2007;8(11):904–16. doi:10.1038/nrm2261
   PubMed Web of Science ®Google Scholar
• Jager M, Nguyen H, Dendle M, et al. Influence of hPin1 WW N-terminal domain boundaries on function, protein stability, and folding. Protein Sci. 2007;16(7):1495–501. doi:10.1110/ps.072775507
   PubMed Web of Science ®Google Scholar
• Liou YC, Zhou XZ, Lu KP. Prolyl isomerase Pin1 as a molecular switch to determine the fate of phosphoproteins. Trends Biochem Sci. 2011;36(10):501–14. doi:10.1016/j.tibs.2011.07.001
   PubMed Web of Science ®Google Scholar
• Lin CH, Li HY, Lee YC, et al. Landscape of Pin1 in the cell cycle. Exp Biol Med (Maywood). 2015;240(3):403–8. doi:10.1177/1535370215570829
   PubMed Web of Science ®Google Scholar
• Liou YC, Sun A, Ryo A, et al. Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature. 2003;424(6948):556–61. doi:10.1038/nature01832
   PubMed Web of Science ®Google Scholar
• Nakamura K, Greenwood A, Binder L, et al. Proline isomer-specific antibodies reveal the early pathogenic tau conformation in Alzheimer's disease. Cell. 2012;149(1):232–44. doi:10.1016/j.cell.2012.02.016
   PubMed Web of Science ®Google Scholar
• Driver JA, Lu KP. Pin1: a new genetic link between Alzheimer's disease, cancer and aging. Curr Aging Sci. 2010;3(3):158–65. doi:10.2174/1874609811003030158
   PubMedGoogle Scholar
• Lee TH, Pastorino L, Lu KP. Peptidyl-prolyl cis-trans isomerase Pin1 in ageing, cancer and Alzheimer disease. Expert Rev Mol Med. 2011;13:e21. doi:10.1017/S1462399411001906
   PubMed Web of Science ®Google Scholar
• Angelucci F, Hort J. Prolyl isomerase Pin1 and neurotrophins: a loop that may determine the fate of cells in cancer and neurodegeneration. Ther Adv Med Oncol. 2017;9(1):59–62. doi:10.1177/1758834016665776
   PubMed Web of Science ®Google Scholar
• Ma LL, Yu JT, Wang HF, et al. Association between cancer and Alzheimer's disease: systematic review and meta-analysis. J Alzheimers Dis. 2014;42(2):565–73.
   PubMed Web of Science ®Google Scholar
• Musicco M, Adorni F, Di Santo S, et al. Inverse occurrence of cancer and Alzheimer disease: a population-based incidence study. Neurology. 2013;81(4):322–8. doi:10.1212/WNL.0b013e31829c5ec1
   PubMed Web of Science ®Google Scholar
• Ayala G, Wang D, Wulf G, et al. The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Res. 2003;63(19):6244–51.
   PubMed Web of Science ®Google Scholar
• Lin FC, Lee YC, Goan YG, et al. Pin1 positively affects tumorigenesis of esophageal squamous cell carcinoma and correlates with poor survival of patients. J Biomed Sci. 2014;21:75. doi:10.1186/s12929-014-0075-1
   PubMed Web of Science ®Google Scholar
• Rudrabhatla P. Regulation of neuronal cytoskeletal protein phosphorylation in neurodegenerative diseases. J Alzheimers Dis. 2014;41(3):671–84.
   PubMed Web of Science ®Google Scholar
• Tenreiro S, Eckermann K, Outeiro TF. Protein phosphorylation in neurodegeneration: friend or foe? Front Mol Neurosci. 2014;7:42.
   PubMed Web of Science ®Google Scholar
• Pastorino L, Sun A, Lu PJ, et al. The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production. Nature. 2006;440(7083):528–34. doi:10.1038/nature04543
   PubMed Web of Science ®Google Scholar
• Ghosh A, Saminathan H, Kanthasamy A, et al. The peptidyl-prolyl isomerase Pin1 up-regulation and proapoptotic function in dopaminergic neurons: relevance to the pathogenesis of Parkinson disease. J Biol Chem. 2013;288(30):21955–71. doi:10.1074/jbc.M112.444224
   PubMed Web of Science ®Google Scholar
• Martin LJ, Pan Y, Price AC, et al. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci. 2006;26(1):41–50. doi:10.1523/JNEUROSCI.4308-05.2006
   PubMed Web of Science ®Google Scholar
• Ryo A, Togo T, Nakai T, et al. Prolyl-isomerase Pin1 accumulates in lewy bodies of parkinson disease and facilitates formation of alpha-synuclein inclusions. J Biol Chem. 2006;281(7):4117–25. doi:10.1074/jbc.M507026200
   PubMed Web of Science ®Google Scholar
• Sorrentino G, Comel A, Mantovani F, et al. Regulation of mitochondrial apoptosis by Pin1 in cancer and neurodegeneration. Mitochondrion. 2014;19(Pt A):88–96. doi:10.1016/j.mito.2014.08.003
   PubMed Web of Science ®Google Scholar
• Grison A, Mantovani F, Comel A, et al. Ser46 phosphorylation and prolyl-isomerase Pin1-mediated isomerization of p53 are key events in p53-dependent apoptosis induced by mutant huntingtin. Proc Natl Acad Sci U S A. 2011;108(44):17979–84. doi:10.1073/pnas.1106198108
   PubMed Web of Science ®Google Scholar
• Soto C, Estrada LD. Protein misfolding and neurodegeneration. Arch Neurol. 2008;65(2):184–9. doi:10.1001/archneurol.2007.56
   PubMedGoogle Scholar
• Anderson JP, Walker DE, Goldstein JM, et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem. 2006;281(40):29739–52. doi:10.1074/jbc.M600933200
   PubMed Web of Science ®Google Scholar
• Weissmann C, Li J, Mahal SP, et al. Prions on the move. EMBO Rep. 2011;12(11):1109–17. doi:10.1038/embor.2011.192
   PubMed Web of Science ®Google Scholar
• Li J, Browning S, Mahal SP, et al. Darwinian evolution of prions in cell culture. Science. 2010;327(5967):869–72. doi:10.1126/science.1183218
   PubMed Web of Science ®Google Scholar
• Ghaemmaghami S, Ahn M, Lessard P, et al. Continuous quinacrine treatment results in the formation of drug-resistant prions. PLoS Pathog. 2009;5(11):e1000673. doi:10.1371/journal.ppat.1000673
   PubMed Web of Science ®Google Scholar
• Bian J, Kang HE, Telling GC. Quinacrine promotes replication and conformational mutation of chronic wasting disease prions. Proceedings of the National Academy of Sciences of the United States of America. 2014;111(16):6028–33. doi:10.1073/pnas.1322377111
   PubMed Web of Science ®Google Scholar
• Hsiao K, Baker HF, Crow TJ, et al. Linkage of a prion protein missense variant to Gerstmann-Straussler syndrome. Nature. 1989;338(6213):342–5. doi:10.1038/338342a0
   PubMed Web of Science ®Google Scholar
• Yamazaki M, Oyanagi K, Mori O, et al. Variant Gerstmann-Straussler syndrome with the P105L prion gene mutation: an unusual case with nigral degeneration and widespread neurofibrillary tangles. Acta Neuropathol. 1999;98(5):506–11. doi:10.1007/s004010051116
   PubMed Web of Science ®Google Scholar
• Fujimori F, Takahashi K, Uchida C, et al. Mice lacking Pin1 develop normally, but are defective in entering cell cycle from G(0) arrest. Biochem Biophys Res Commun. 1999;265(3):658–63. doi:10.1006/bbrc.1999.1736
   PubMed Web of Science ®Google Scholar
• Denk F, Wade-Martins R. Knock-out and transgenic mouse models of tauopathies. Neurobiol Aging. 2009;30(1):1–13. doi:10.1016/j.neurobiolaging.2007.05.010
   PubMed Web of Science ®Google Scholar
• Morales R, Duran-Aniotz C, Diaz-Espinoza R, et al. Protein misfolding cyclic amplification of infectious prions. Nat Protoc. 2012;7(7):1397–409. doi:10.1038/nprot.2012.067
   PubMed Web of Science ®Google Scholar